Structures by: Wong A. B.
Total: 39
Oxaprozin-1,2-bis(4-pyridyl)ethane
C18H15NO3,C6H6N
RSC Adv. (2016)
a=9.7069(19)Å b=10.878(2)Å c=10.907(2)Å
α=76.50(3)° β=68.03(3)° γ=66.04(3)°
Oxaprozin-Salbutamol
C13H22NO3,C18H14NO3
RSC Adv. (2016)
a=10.453(2)Å b=10.627(2)Å c=13.379(3)Å
α=76.02(3)° β=69.82(3)° γ=88.05(3)°
Oxaprozin-4,4'-Bipyridine
C18H15NO3,C5H4N
RSC Adv. (2016)
a=13.422(3)Å b=15.305(3)Å c=18.618(4)Å
α=90.00° β=103.53(3)° γ=90.00°
Oxaprozin
C18H15NO3
RSC Adv. (2016)
a=10.3129(5)Å b=7.6460(3)Å c=36.7642(15)Å
α=90.00° β=90.00° γ=90.00°
Oxaprozin-piperazine
C18H14NO3,C2H6N
RSC Adv. (2016)
a=5.8155(12)Å b=7.3355(15)Å c=19.744(4)Å
α=90.14(3)° β=91.13(3)° γ=99.08(3)°
Oxaprozin-2-Amino-3-Picoline
C18H14NO3,C6H9N2
RSC Adv. (2016)
a=6.0156(12)Å b=8.8644(18)Å c=19.296(4)Å
α=81.31(3)° β=85.29(3)° γ=80.23(3)°
Triflusal-BA cocrystal
C10H7F3O4,C7H7NO
CrystEngComm (2015) 17, 48 9323
a=5.1765(10)Å b=15.228(3)Å c=21.041(4)Å
α=90° β=93.91(3)° γ=90°
Triflusal-Isonicotinamide cocrystal
C10H7F3O4,C6H6N2O
CrystEngComm (2015) 17, 48 9323
a=17.345(7)Å b=5.1415(17)Å c=19.447(7)Å
α=90° β=112.506(5)° γ=90°
Triflusal-2-Picoliniamide cocrystal
C10H7F3O4,C6H6N2O
CrystEngComm (2015) 17, 48 9323
a=5.5536(11)Å b=11.950(2)Å c=12.200(2)Å
α=96.01(3)° β=94.85(3)° γ=95.99(3)°
Triflusal-urea cocrystal
CH4N2O,2(C10H7F3O4)
CrystEngComm (2015) 17, 48 9323
a=14.601(3)Å b=10.920(2)Å c=15.342(3)Å
α=90° β=102.49(3)° γ=90°
Triflusal-Propionamide cocrystal
C10H7F3O4,C3H7NO
CrystEngComm (2015) 17, 48 9323
a=18.729(6)Å b=9.921(3)Å c=8.067(3)Å
α=90° β=97.605(4)° γ=90°
Triflusal-valpromide cocrystal
C10H7F3O4,C8H17NO
CrystEngComm (2015) 17, 48 9323
a=19.8545(8)Å b=5.06409(17)Å c=21.8530(11)Å
α=90° β=114.362(6)° γ=90°
1:1 ethenzamide and salicylic acid cocrystal
C9H11NO2,C7H6O3
CrystEngComm (2012) 14, 24 8515
a=10.679(2)Å b=9.6670(19)Å c=14.845(3)Å
α=90.00° β=106.97(3)° γ=90.00°
1:1 ethenzamide and vanillic acid cocrystal
C9H11NO2,C8H8O4
CrystEngComm (2012) 14, 24 8515
a=13.774(3)Å b=14.911(3)Å c=8.0828(16)Å
α=90.00° β=102.87(3)° γ=90.00°
1:1 cocrystal of ethenzamide and 2-chloro-4-nitrobenzoic acid
C9H11NO2,C7H4ClNO4
CrystEngComm (2012) 14, 24 8515
a=7.7402(15)Å b=8.3181(17)Å c=13.216(3)Å
α=76.02(3)° β=79.85(3)° γ=84.69(3)°
2:1 ethenzamide and 4-aminobenzoic acid cocrystal
2(C9H11NO2),C7H7NO2
CrystEngComm (2012) 14, 24 8515
a=9.0570(18)Å b=32.685(7)Å c=8.1857(16)Å
α=90.00° β=93.39(3)° γ=90.00°
1:1 ethenzamide and 4-hydroxybenzoic acid
C9H11NO2,C7H6O3
CrystEngComm (2012) 14, 24 8515
a=9.4871(19)Å b=6.4682(13)Å c=23.703(5)Å
α=90.00° β=98.65(3)° γ=90.00°
1:0.5 ethenzamide and fumaric acid cocrystal
C9H11NO2,0.5(C4H4O4)
CrystEngComm (2012) 14, 24 8515
a=8.2154(16)Å b=8.4654(17)Å c=9.3991(19)Å
α=70.30(3)° β=71.82(3)° γ=65.97(3)°
C21H18F3N5O4
C21H18F3N5O4
CrystEngComm (2014) 16, 26 5793
a=6.9931(14)Å b=10.127(2)Å c=15.112(3)Å
α=95.46(3)° β=96.70(3)° γ=101.17(3)°
C19H15F3N2O3
C19H15F3N2O3
CrystEngComm (2014) 16, 26 5793
a=7.5628(15)Å b=7.6450(15)Å c=14.552(3)Å
α=90.45(3)° β=92.14(3)° γ=95.81(3)°
C38H28F6N4O4
C38H28F6N4O4
CrystEngComm (2014) 16, 26 5793
a=9.827(2)Å b=10.361(2)Å c=25.005(5)Å
α=84.67(3)° β=81.34(3)° γ=71.46(3)°
C13H15N3O5
C13H15N3O5
CrystEngComm (2013) 15, 29 5877
a=7.0070(14)Å b=11.224(2)Å c=16.950(3)Å
α=90.00° β=91.95(3)° γ=90.00°
C13H15N3O5
C13H15N3O5
CrystEngComm (2013) 15, 29 5877
a=6.8143(14)Å b=22.419(5)Å c=8.8759(18)Å
α=90.00° β=101.85(3)° γ=90.00°
C16H18N6O6
C16H18N6O6
CrystEngComm (2013) 15, 29 5877
a=7.8906(16)Å b=8.7030(17)Å c=12.517(3)Å
α=90.00° β=97.84(3)° γ=90.00°
C16H18N6O6
C16H18N6O6
CrystEngComm (2013) 15, 29 5877
a=3.7036(7)Å b=7.8401(16)Å c=29.573(6)Å
α=90.00° β=90.63(3)° γ=90.00°
C16H17N5O6
C16H17N5O6
CrystEngComm (2013) 15, 29 5877
a=5.0595(10)Å b=17.246(3)Å c=19.056(4)Å
α=90.00° β=97.25(3)° γ=90.00°
C16H19N5O6
C16H19N5O6
CrystEngComm (2013) 15, 29 5877
a=5.1175(10)Å b=17.467(4)Å c=18.763(4)Å
α=90.00° β=96.71(3)° γ=90.00°
Form 1 of 1:1 nicotinamide and pimelic acid
C7H12O4,C6H6N2O
CrystEngComm (2012) 14, 23 8193
a=5.4242(11)Å b=7.3161(15)Å c=17.917(4)Å
α=99.69(3)° β=94.01(3)° γ=103.93(3)°
Form 2 of 1:1 nicotinamide and pimelic acid
C7H12O4,C6H6N2O
CrystEngComm (2012) 14, 23 8193
a=9.290(7)Å b=31.04(2)Å c=4.981(4)Å
α=90.00° β=90.00° γ=90.00°
Haloperidol-oxalic acid dihydrate
C44H52Cl2F2N2O10
Crystal Growth & Design (2014) 14, 5 2542
a=11.961(2)Å b=12.954(3)Å c=14.825(3)Å
α=114.00(3)° β=99.25(3)° γ=90.72(3)°
ACN solvate of HAL and OA salt
C46H51Cl2F2N3O8
Crystal Growth & Design (2014) 14, 5 2542
a=13.125(3)Å b=11.996(2)Å c=26.810(5)Å
α=90.00° β=90.06(3)° γ=90.00°
Haloperidol-fumaric acid salt dihydrate
C23H29ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.7151(17)Å b=10.152(2)Å c=14.454(3)Å
α=97.42(3)° β=98.87(3)° γ=114.92(3)°
Haloperidol-succinic acid salt hydrate
C23H30ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.6026(17)Å b=10.585(2)Å c=13.862(3)Å
α=108.39(3)° β=101.96(3)° γ=99.31(3)°
Haloperidol-Acetic acid salt dihydrate
C23H31ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.7476(17)Å b=10.374(2)Å c=13.837(3)Å
α=105.57(3)° β=100.04(3)° γ=96.10(3)°
Haloperidol-Formic acid salt
C23H27ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.4958(17)Å b=10.032(2)Å c=26.324(5)Å
α=90.00° β=94.46(3)° γ=90.00°
1:1 salt of haloperidol and saccharin
C28H28ClFN2O5S
Crystal Growth & Design (2014) 14, 5 2542
a=11.189(2)Å b=19.890(4)Å c=12.562(3)Å
α=90.00° β=114.22(3)° γ=90.00°
1:1 salt of HAL and CSA
C27H36ClFN2O5S
Crystal Growth & Design (2014) 14, 5 2542
a=8.4571(17)Å b=9.768(2)Å c=17.989(4)Å
α=87.28(3)° β=86.32(3)° γ=68.48(3)°
Form II of a 1:1 salt of HAL and ACE-H
C25H28ClFN2O6S
Crystal Growth & Design (2014) 14, 5 2542
a=9.5340(19)Å b=10.120(2)Å c=14.360(3)Å
α=88.15(3)° β=83.73(3)° γ=65.69(3)°
Form I of a 1:1 salt of HAL and ACE-H
C25H28ClFN2O6S
Crystal Growth & Design (2014) 14, 5 2542
a=26.571(5)Å b=9.925(2)Å c=21.954(4)Å
α=90.00° β=120.59(3)° γ=90.00°